brexus -Cell治疗复发/难治性b细胞急性淋巴细胞白血病和套细胞淋巴瘤的成本-效果研究:一项系统综述。

IF 1.8 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES
Asmita Priyadarshini Khatiwada, Ahmed Mostafa Ahmed Kamel, Nathorn Chaiyakunapruk, Surachat Ngorsuraches
{"title":"brexus -Cell治疗复发/难治性b细胞急性淋巴细胞白血病和套细胞淋巴瘤的成本-效果研究:一项系统综述。","authors":"Asmita Priyadarshini Khatiwada, Ahmed Mostafa Ahmed Kamel, Nathorn Chaiyakunapruk, Surachat Ngorsuraches","doi":"10.1080/14737167.2024.2438631","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This systematic review aims to explore the existing evidence on the cost-effectiveness of brexu-cel across different international jurisdictions.</p><p><strong>Methods: </strong>A systematic search of articles on Embase, Medline, Econlit, Web of Science, Scopus, gray literature, and a manual search of HTA reports was done until 24 June 2024. Original English articles and reports from different countries assessing the cost-effectiveness of brexu-cel in relapsed/refractory acute lymphoblastic leukemia (R/R ALL) and mantle cell lymphoma (R/R MCL) were included. This review was registered in the Open Science Framework (OSF) registry.</p><p><strong>Results: </strong>Of the 149 records, 22 articles underwent full-text review after the title and abstract screening, five met the inclusion criteria along with seven HTA reports from Australia, Canada, Scotland, and England. The CEA studies were from the US, England, Canada, and Italy, with varying perspectives, mainly adopting a partitioned survival model and lifetime horizons. The model input data from the ZUMA-2 and ZUMA-3 trials were used for brexu-cel, with comparisons from their respective trials or literature.</p><p><strong>Conclusion: </strong>Brexu-cel was found cost-effective in all the CEA studies and an HTA report from Scotland, but the other HTA agencies reported uncertainties around the cost-effectiveness of brexu-cel for R/R ALL and R/R MCL.</p><p><strong>Registration: </strong>Open Science Framework. (Reg doi: https://doi.org/10.17605/OSF.IO/JZU6Y).</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-13"},"PeriodicalIF":1.8000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cost-effectiveness studies of brexu-cel for relapsed/refractory B-cell acute lymphoblastic leukemia and mantle cell lymphoma: a systematic review.\",\"authors\":\"Asmita Priyadarshini Khatiwada, Ahmed Mostafa Ahmed Kamel, Nathorn Chaiyakunapruk, Surachat Ngorsuraches\",\"doi\":\"10.1080/14737167.2024.2438631\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>This systematic review aims to explore the existing evidence on the cost-effectiveness of brexu-cel across different international jurisdictions.</p><p><strong>Methods: </strong>A systematic search of articles on Embase, Medline, Econlit, Web of Science, Scopus, gray literature, and a manual search of HTA reports was done until 24 June 2024. Original English articles and reports from different countries assessing the cost-effectiveness of brexu-cel in relapsed/refractory acute lymphoblastic leukemia (R/R ALL) and mantle cell lymphoma (R/R MCL) were included. This review was registered in the Open Science Framework (OSF) registry.</p><p><strong>Results: </strong>Of the 149 records, 22 articles underwent full-text review after the title and abstract screening, five met the inclusion criteria along with seven HTA reports from Australia, Canada, Scotland, and England. The CEA studies were from the US, England, Canada, and Italy, with varying perspectives, mainly adopting a partitioned survival model and lifetime horizons. The model input data from the ZUMA-2 and ZUMA-3 trials were used for brexu-cel, with comparisons from their respective trials or literature.</p><p><strong>Conclusion: </strong>Brexu-cel was found cost-effective in all the CEA studies and an HTA report from Scotland, but the other HTA agencies reported uncertainties around the cost-effectiveness of brexu-cel for R/R ALL and R/R MCL.</p><p><strong>Registration: </strong>Open Science Framework. (Reg doi: https://doi.org/10.17605/OSF.IO/JZU6Y).</p>\",\"PeriodicalId\":12244,\"journal\":{\"name\":\"Expert Review of Pharmacoeconomics & Outcomes Research\",\"volume\":\" \",\"pages\":\"1-13\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-12-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Pharmacoeconomics & Outcomes Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737167.2024.2438631\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2024.2438631","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

引言:本系统综述旨在探讨不同国际司法管辖区关于brexeu -cel成本效益的现有证据。方法:系统检索Embase、Medline、Econlit、Web of Science、Scopus、灰色文献,手工检索HTA报告,直至2024年6月24日。来自不同国家的英文原创文章和报告评估了brexus - cell治疗套细胞淋巴瘤(MCL)和急性淋巴细胞白血病(ALL)的成本-效果。该综述已在开放科学框架(OSF)注册中心注册。(Reg doi: https://doi.org/10.17605/OSF.IO/JZU6Y).Results)在149篇文献中,22篇文献在标题和摘要筛选后进行了全文审查,其中5篇符合纳入标准,7篇来自澳大利亚、加拿大、苏格兰和英国的HTA报告也符合纳入标准。CEA的研究来自美国、英国、加拿大和意大利,从不同的角度进行研究,主要采用了分区的生存模型和生命周期。将ZUMA-2和ZUMA-3试验的模型输入数据用于brexucel,并与各自的试验或文献进行比较。结论:在所有CEA研究和苏格兰HTA报告中发现brexux -cel具有成本效益,但其他HTA机构报告了brexux -cel治疗R/R all和R/R MCL的成本效益的不确定性。注册:开放科学框架;(注册doi: https://doi.org/10.17605/OSF.IO/JZU6Y)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cost-effectiveness studies of brexu-cel for relapsed/refractory B-cell acute lymphoblastic leukemia and mantle cell lymphoma: a systematic review.

Introduction: This systematic review aims to explore the existing evidence on the cost-effectiveness of brexu-cel across different international jurisdictions.

Methods: A systematic search of articles on Embase, Medline, Econlit, Web of Science, Scopus, gray literature, and a manual search of HTA reports was done until 24 June 2024. Original English articles and reports from different countries assessing the cost-effectiveness of brexu-cel in relapsed/refractory acute lymphoblastic leukemia (R/R ALL) and mantle cell lymphoma (R/R MCL) were included. This review was registered in the Open Science Framework (OSF) registry.

Results: Of the 149 records, 22 articles underwent full-text review after the title and abstract screening, five met the inclusion criteria along with seven HTA reports from Australia, Canada, Scotland, and England. The CEA studies were from the US, England, Canada, and Italy, with varying perspectives, mainly adopting a partitioned survival model and lifetime horizons. The model input data from the ZUMA-2 and ZUMA-3 trials were used for brexu-cel, with comparisons from their respective trials or literature.

Conclusion: Brexu-cel was found cost-effective in all the CEA studies and an HTA report from Scotland, but the other HTA agencies reported uncertainties around the cost-effectiveness of brexu-cel for R/R ALL and R/R MCL.

Registration: Open Science Framework. (Reg doi: https://doi.org/10.17605/OSF.IO/JZU6Y).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Expert Review of Pharmacoeconomics & Outcomes Research
Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY
CiteScore
4.00
自引率
4.30%
发文量
68
审稿时长
6-12 weeks
期刊介绍: Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信